- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Segment 4: Making Cost-Based Treatment Decisions
Harvoni has shown results within the first 8 weeks of treatment, which would save costs, Matthew D. Harman, PharmD, MPH, does not think many patients or providers will be making cost-based hepatitis C treatment decisions.
Harvoni has shown results within the first 8 weeks of treatment, which would save costs, Matthew D. Harman, PharmD, MPH, does not think many patients or providers will be making cost-based hepatitis C treatment decisions. Typically, less than 30% of providers are actually aware of medication costs, he said.
Express Scripts calculated the cost across the 8-, 12-, and 24-week regimens and found that even with the best rate for Harvoni, the cost of treatment is still in favor of Viekira Pak by about $10,000 per treatment, which benefits plan sponsors struggling to make ends meet.
“Plans sponsors have to choose what’s right for them,” he said.
Nomogram Aids Early Detection of Myasthenic Crisis Risk
August 19th 2025Despite nurses often being the first health care workers many patients encounter, they frequently lack adequate tools to optimally evaluate their patients’ conditions, as in the case with myasthenia gravis and being able to predict patients at risk of myasthenic crisis.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
